The Orphan Drug Act

Historically, pharmaceutical companies have focused their efforts on developing so-called ‘blockbuster' drugs, i.e. those drugs that treat common conditions, with large patient populations, and that are expected to generate revenues greater than $1 billion per [...]

By |2021-03-15T11:42:37+00:00January 27th, 2017|Big Pharma|

Exciting news for Biosimilars

It’s been an exciting start to the new year for the biosimilar industry. The FDA has released a finalized guidance document for developing biosimilar drugs, which clarifies how drug makers can prove that their drug [...]

By |2021-03-15T11:55:48+00:00January 6th, 2017|Reference Listed Drug|
Go to Top